Laserable and releasable sutures preferable after trabeculectomy

Article

Laser suture lysis or releasable suture techniques can be a preferable alternative to permanent sutures for closing scleral flaps in primary trabeculectomy with mitomycin C (MMC) in uncomplicated glaucoma, according to a study published in the March issue of Journal of Glaucoma.

Laser suture lysis or releasable suture techniques can be a preferable alternative to permanent sutures for closing scleral flaps in primary trabeculectomy with mitomycin C (MMC) in uncomplicated glaucoma, according to a study published in the March issue of Journal of Glaucoma.

The study, conducted by Dr Umit Aykan and colleagues, compared the efficacy and complication rates of laser suture lysis (LSL) or releasable suture techniques after trabeculectomy. The study analysed 48 eyes of 43 patients with uncomplicated glaucoma who were recruited for primary trabeculectomy with MMC. The patients were divided into two groups of 27 and 21 eyes that were randomly assigned to a standard surgery and releasable suture groups respectively. A target intraocular pressure (IOP) was determined on the basis of the severity of the glaucoma and was called a complete success, qualified success or failure.

Group 1 recorded a mean change in IOP after LSL of 7.31±1.98 mmHg, 6.1±1.1 mmHg and 3.9±1.5 mmHg when sutures were lysed on the first, second and third months, respectively. In group 2, the mean change in IOP after releasable suture removal was 8.20±2.74 mmHg, 5.12±1.65 mmHg and 4.4±1.0 mmHg, respectively. After six months, the success rates were 92% and 90% for LSL and releasable suture groups, respectively.

The study concluded that there is an effective IOP reduction in eyes that had suture release both in the early and late postoperative periods after LSL and suture release. Both the laserable and releasable suture techniques can therefore be preferred to permanent sutures for closing scleral flaps in primary trabeculectomy with MMC in uncomplicated glaucoma.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.